UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

^{______________}

FORM 10-QSB

^{______________}

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2007

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ____________ to____________

Commission File No. 000-24480

SANGUINE CORPORATION

(Exact name of small business issuer as specified in its charter)

Nevada	95-4347608
(State or Other Jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

101 East Green Street, #6

Pasadena, California 91105

(Address of Principal Executive Offices)

(626) 405-0079

(Issuer’s Telephone Number)

N/A

(Former name, former address and former fiscal year,

if changed since last report)

Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

Indicate by check mark whether the Issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ] No [X]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Not applicable.

Check whether the Issuer filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.  Yes [  ] No [  ]

1

Not applicable.

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the Issuer’s classes of common equity, as of the latest practicable date: August 8, 2007 - 89,092,825 shares of common stock.

Transitional Small Business Disclosure Format (Check one): Yes [  ] No [X]

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

2

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2007 and December 31, 2006

3

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

Consolidated Balance Sheets

ASSETS

		June 30, 2007		December 31, 2006
		(Unaudited)
CURRENT ASSETS
Cash	$	6,487	$	30,288
Prepaid expense		688,484		-
Total Current Assets		694,971		30,288
PROPERTY AND EQUIPMENT, NET		819		968
TOTAL ASSETS	$	695,790	$	31,256

The accompanying notes are an integral part of these consolidated financial statements.

4

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

Consolidated Balance Sheets (Continued)

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

		June 30, 2007		December 31, 2006
		(Unaudited)
CURRENT LIABILITIES
Related party payables	$	-	$	4,000
Accounts payable		319,306		323,370
Warrant liability		2,169		2,123
Accrued compensation		26,813		78,937
Total Current Liabilities		348,288		408,430
Total Liabilities		348,288		408,430
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY (DEFICIT)
Common stock, 200,000,000 shares authorized   of $0.001 par value, 89,092,825 and 81,683,658 shares        issued and outstanding, respectively		89,093		81,684
Common stock subscribed		-		27,800
Additional paid in capital		7,052,626		5,873,443
Accumulated other comprehensive income (loss)		(5,445)		(2,570)
Deficit accumulated during the development stage		(6,788,772)		(6,357,531)
Total Shareholders’ Equity (Deficit)		347,502		(377,174)
TOTAL LIABILITIES AND SHAREHOLDERS’   EQUITY (DEFICIT)	$	695,790	$	31,256

The accompanying notes are an integral part of these consolidated financial statements.

5

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

Consolidated Statements of Operations and Other Comprehensive Income (Loss)

(Unaudited)

		For the Three Months Ended  June 30,									For the Six Months Ended June 30,					From Inception of the Development Stage on January 18, 1990 through June 30,
			2007			2006			2007				2006			2007
REVENUES	$			-	$		500	$		-		$		5,563	$		181,762
OPERATING EXPENSES
Professional fees				134,561			13,967			155,666				29,898			3,051,844
Research and    Development				-			100,269			72,182				135,178			1,971,831
Selling, general and    Administrative				115,428			75,836			127,350				99,631			2,728,982
Total Operating Expenses				249,989			190,072			355,198				264,707			7,752,657
LOSS FROM OPERATIONS				(249,989)			(189,572)			(355,198)				(259,144)			(7,570,894)
OTHER INCOME (EXPENSE)
Interest income				37			523			78				1,487			39,343
Interest expense				-			-			-				-			(667,986)
Loss on cash deposit				-			-			-				-			(10,020)
Warrant expense				(76,122)			-			(76,122)				-			(76,122)
Gain on settlement of    Debt				-			-			-				-			1,496,907
Total Other Income (Expense)				(76,085)			523			(76,044)				1,487			782,122
NET INCOME (LOSS)				(326,074)			(189,049)			(431,242)				(257,657)			(6,788,772)

The accompanying notes are an integral part of these consolidated financial statements.

6

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

Consolidated Statements of Operations and Other Comprehensive Income (Loss)-continued

(Unaudited)

For the Three Months Ended June 30,			For the Six Months Ended June 30,		From Inception of the Development Stage on January 18, 1990 through June 30,
2007	2006	2007		2006	2007

OTHER COMPREHENSIVE INCOME (LOSS)
Loss on foreign currency exchange		(1,283)		-		(2,875)		-		(5,445)
TOTAL COMPREHENSIVE INCOME (LOSS)	$	(327,357)	$	(189,049)	$	(434,117)	$	(257,657)	$	(6,794,217)
BASIC INCOME (LOSS) PER SHARE	$	(0.00)	$	(0.00)	$	(0.01)	$	(0.00)
DILUTED INCOME PER SHARE	$	(0.00)	$	(0.00)	$	(0.01)	$	(0.00)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING –BASIC		88,488,430		81,040,325		85,379,901		80,885,649
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING-DILUTED		88,488,430		81,040,325		85,379,901		80,885,649

The accompanying notes are an integral part of these consolidated financial statements.

7

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

Consolidated Statements of Cash Flows (Continued)

(Unaudited)

	For the Six Months Ended June 30,							From Inception of the Development Stage on January 18, 1990 through June 30,
	2007			2006				2007
Net loss		$	(431,242)		$	(257,657)	$		(6,788,772)
Adjustments to reconcile net loss to net cash used  by operating activities:
Depreciation			149			149			5,281
Common stock issued for services			277,188			43,812			2,936,337
Contributed capital			-			-			520
Stock options granted			76,122			-			76,122
Stock warrants granted			-			-			8,650
Interest on beneficial conversion feature			-			-			25,000
Legal expense related to beneficial conversion feature			-			-			3,750
Note payable issued for services			-			-			727,950
Gain on extinguishments of debt			-			-			(98,826)
Gain on conversions of debt to equity			-			-			(1,398,081)
Recognition of prepaid expenses and      expenses prepaid with common stock			-			-			456,184
Changes in assets and liabilities:
Increase in accounts payable and related party payables			(10,939)			48,162			638,048
Increase in accrued interest payable			-			-			547,279
Increase in accrued liabilities			-			-			10,125
Increase in customer deposits`			-			-			45,000
Increase (decrease) in warrant liability			46			17,578			2,169
Increase in accrued salaries			(52,124)			21,812			860,688
Net Cash Used by Operating Activities			(140,800)			(126,144)			(1,942,576)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for fixed assets			-			-			(6,100)
Net Cash Used by Investing Activities			-			-			(6,100)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from warrant conversion			100,000			20,000			524,700
Proceeds from notes payable and notes payable-     related party			-			-			212,139
Payments on notes payable and notes payable –     related party			-			-			(9,400)
Proceeds from issuance of convertible debentures			-			-			40,000
Contributed capital			-			-			750
Common stock issued for cash			16,999			-			1,186,974
Net Cash Provided by Financing Activities			116,999			20,000			1,955,163
NET INCREASE (DECREASE) IN CASH			(23,801)			(106,144)			6,487
CASH AT BEGINNING OF PERIOD			30,288			159,466			-
CASH AT END OF PERIOD		$	6,487		$	53,322	$		6,487

The accompanying notes are an integral part of these consolidated financial statements.

8

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

 Consolidated Statements of Cash Flows

(Unaudited)

For the Six Months Ended June 30,		From Inception of the Development Stage on January 18, 1990 through June 30,
2007	2006	2007

SUPPLEMENTAL SCHEDULE OF CASH FLOW ACTIVITIES
CASH PAID FOR:
Interest	$	-	$	-	$	-
Income taxes	$	-	$	-	$	-
NON-CASH ACTIVITIES
Common stock issued for debt conversion	$	-	$	-	$	9,600
Equity instruments issued for services rendered	$	353,310	$	-	$	3,012,459
Contributed capital for interest contributed	$	-	$	-	$	520
Interest on beneficial conversion feature	$	-	$	-	$	25,000
Legal related to beneficial conversion feature	$	-	$	-	$	3,750
Notes payable issued for services	$	-	$	-	$	727,950
Common stock issued for prepaid services	$	-	$	-	$	236,284
Common stock issued for debt	$	-	$	-	$	2,822,067

The accompanying notes are an integral part of these consolidated financial statements.

9

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements

June 30, 2007 and December 31, 2006

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted in accordance with such rules and regulations.  The information furnished in the interim consolidated financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements.  Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim consolidated financial statements be read in conjunction with the Company’s most recent audited financial statements and notes thereto included in its December 31, 2006 Annual Report on Form 10-KSB.  Operating results for the three and six months ended June 30, 2007 are not necessarily indicative of the results that may be expected for the year ending December 31, 2007.

NOTE 2 - GOING CONCERN

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern.  The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.  If the Company is unable to obtain adequate capital, it could be forced to cease operations.

The Company’s management has taken certain steps to maintain its operating and financial requirements in an effort to continue as a going concern until such time as revenues are sufficient to cover expenses.  Future plans include a debt or equity offering for between $1,000,000 - $1,500,000 that should enable the Company to complete the animal testing stage for FDA approval of its product.  However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations.  The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

10

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements

June 30, 2007 and December 31, 2006

NOTE 3 -STOCK OPTIONS AND WARRANTS

A summary of the status of the Company’s outstanding stock warrants as of June 30, 2007 and December 31, 2006 and changes during the periods then ended is presented below:

	2007			2006
	Shares	Weighted Average Exercise Price		Shares	Weighted Average Exercise Price
Outstanding, beginning of year	2,123,115	$	0.08	2,843,757	$	0.15
Granted	-		-	-		-
Expired/Cancelled	(150,000)		0.125	(470,642)		0.13
Exercised	(1,250,000)		0.08	(250,000)		0.08
Outstanding end of year	723,115	$	0.08	2,123,115	$	0.08
Exercisable	723,115	$	0.08	2,123,115	$	0.08

		Outstanding				Exercisable
Range of Exercise Prices			Number outstanding at June 30, 2007	Weighted Average Remaining Contractual Life	Number Exercisable at June 30,2007
$	0.08		693,115	.70	693,115
	0.028		30,000	.90	30,000
			723,115		723,115

A summary of the status of the Company’s outstanding stock options as of June 30, 2007 and December 31, 2006 and changes during the periods then ended is presented below:

	2007			2006
	Shares	Weighted Average Exercise Price		Shares	Weighted Average Exercise Price
Outstanding, beginning of year	-	$	-	-	$	-
Granted	5,000,000		0.06	-		-
Expired/Cancelled	-		-	-		-
Exercised	-		-	-		-
Outstanding end of year	5,000,000	$	0.06	-	$	-
Exercisable	5,000,000	$	0.06	-	$	-

11

SANGUINE CORPORATION & SUBSIDIARY

(A Development Stage Company)

Notes to Consolidated Financial Statements

June 30, 2007 and December 31, 2006

NOTE 3 -STOCK OPTIONS AND WARRANTS (Continued)

		Outstanding				Exercisable
Range of Exercise Prices			Number outstanding at June 30, 2007	Weighted Average Remaining Contractual Life	Number Exercisable at June 30,2007
$	0.06		5,000,000	1.75	5,000,000
			5,000,000		5,000,000

During the three months ended June 30, 2007, the Company granted 5,000,000 options to purchase the Company’s common stock for an exercise price of $0.06 per share for a period of 24 months beginning in April 2007.  The options were granted as part of a consulting agreement with LKB Partners, LLC entered into during the quarter.  The Company valued the options using the Black-Scholes option-pricing model with the following assumptions: dividend yield of zero percent; expected volatility of 75.6%; risk-free interest rate of 4.73%; and expected life of 2 years.  The value of the options was initially recorded as a prepaid expense which is being amortized over the 15 month term of the consulting agreement which expires on June 30, 2008.

NOTE 4 - EQUITY TRANSACTIONS

During the six months ended June 30, 2007, the Company issued 532,500 shares of common stock for services valued at a range of $0.09-$0.23 per share for a total of $181,188; 1,533,334 shares issued for warrants exercises valued at a range of $0.06-$0.08 per share for a total of $117,000; 5,000,000 shares issued pursuant to a consulting agreement valued at $0.12 per share for a total of $600,000 of which $480,000 was initially recorded as a prepaid asset and is being amortized over the 15 month term of the consulting agreement.

Common stock issued for services, prepaid services and cash-less option exercises have been accounted for at the fair market value of the securities on the date of issue.

12

Item 2. Management’s Discussion and Analysis or Plan of Operation.

Forward-looking Statements

Statements made in this Quarterly Report which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company, including, without limitation, (i) the Company’s ability to raise capital, and (ii) statements preceded by, followed by or that include the words “may”, “would”, “could”, “should”, “expects”, “projects”, “anticipates”, “believes”, “estimates”, “plans”, “intends”, “targets” or similar expressions.

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Company’s control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following, general economic or industry conditions, nationally and/or in the communities in which the Company may conduct business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, the Company’s ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting the Company’s operations, products, services and prices.

Accordingly, results actually achieved may differ materially from expected results in these statements.  Forward-looking statements speak only as of the date they are made.  The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

Plan of Operation

We have not commenced planned principal operations, but have made good progress since the end of fiscal 2005, in formulation and stability testing.

In January, 2005, we were successful in developing improved formulations of our surfactants for PHER-02.

In December, 2006, we completed a pre-IND meeting with the FDA, where Company management presented data to determine an appropriate regulatory path related to PHER-O2.

Our plan of operation for the next 12 months is to complete the preparation and submission of the U.S. FDA New Device Application to support PHER-02 as a synthetic oxygen carrying product.

Our proposed plan of operation is composed of “stages,” each of which coincides with a specific milestone in the process of developing PHER-O2.  Each stage, and the projected cost of each, is as follows:

Stage A (approximately three-six months): Complete the development of perfluoro-decalin and the synthetic surfactants that make up PHER-O2, manufactured experimental doses in accordance with FDA and overseas regulations and submit data to support a Master Drug Filing.  Estimated cost is not to exceed $500,000, divided as follows: Completed surfactant formulation (done) and the manufacture of sufficient product for testing, (on going); animal safety and efficacy trials through a sub-contractor, (done); and administrative, patent and proprietary right protection and marketing costs,(in process) Optimize stabilized product to support the Master Drug Filing (in process).

Stage B (approximately three-six months): In the second period, we will produce optimal quantities and conduct testing in accordance with FDA and overseas requirements.  During the course of Stage A, we estimate that our increased technical, administrative, sales/marketing and manufacturing requirements will require us to the hire a few additional contractors and/or employees.  

13

Stage C (approximately three-six months): In the third period, we intend to prepare new 510(k) device application with the FDA.  Estimated cost is $1,000,000, to be used as follows: set-up pilot facility, or subcontractor, to manufacture small quantities of PHER-O2 for use in testing and in connection with the New Drug Applications [done], prepare and submit data for use of PHER-O2 as a whole organ transportation medium in support of FDA labeling, and administrative, patent and proprietary right protection and marketing costs, (in process).

These cost estimates are based upon the prior experience of Thomas C. Drees, Ph.D., our President and CEO.  Dr. Drees has more than 33 years’ experience in the blood industry with Abbott Scientific, Alpha Therapeutics and Sanguine Corporation.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Three Months Ended June 30, 2007, Compared to the Three Months Ended June 30, 2006

Revenues for the quarters ending June 30, 2007, and 2006, were $0 and $500, respectively.  We had no material operations, except the research and development activities related to our subcontracted research and development of our product, PHER-O2.

We realized a total comprehensive loss of $327,357 for the quarter ended June 30, 2007, and a net loss of $189,049 for the quarter ended June 30, 2006.  Most of our expense related to research and development in 2006.

Our research and development expenses were $0 for the quarter ended June 30, 2007, compared to $100,269 in the same period of 2006.

During the three months ended June 30, 2007, the Company issued 4,000,000 shares of common stock and granted 5,000,000 options to purchase common stock in connection with a consulting agreement.  Both the shares and stock options have been valued at fair market value as of the date of issuance and grant.  The value of the shares and options was initially recorded as a prepaid expense which is being amortized over the 15 month term of the consulting agreement which expires on June 30, 2008.  For the three months ended June 30, 2007, the Company recognized $172,121 as an expense related to these shares and options.

Six Months Ended June 30, 2007, Compared to the Six Months Ended June 30, 2006

Revenues for the six months ended June 30, 2007, and 2006, were $0 and $5,563, respectively.  We had no material operations, except the research and development activities related to our subcontracted research and development of our product, PHER-O2.

We realized a total comprehensive loss of $434,117 for the six months ended June 30, 2007, and a net loss of $257,657 for the six months ended June 30, 2006.  Most of our expense related to research and development in 2006.

Our research and development expenses were $72,182 for the six months ended June 30, 2007, compared to $135,178 in the same period of 2006.

During the six months ended June 30, 2007, the Company issued 4,000,000 shares of common stock and granted 5,000,000 options to purchase common stock in connection with a consulting agreement.  Both the shares and stock options have been valued at fair market value as of the date of issuance and grant.  The value of the shares and options was initially recorded as a prepaid expense which is being amortized over the 15 month term of the consulting agreement which expires on June 30, 2008.  For the three months ended June 30, 2007, the Company recognized $172,121 as an expense related to these shares and options.

Liquidity

As of June 30, 2007, we had $6,487 in cash, with $348,288 in current liabilities.

14

During the latter part of 2006, we sold 746,667 shares of our common stock that were “restricted securities” as defined in Rule 144 of the Securities and Exchange Commission having been sold for gross proceeds of approximately $44,800.

The Company plans to fund our proposed “stages” of operations by additional private placements of debt or equity securities or a combination of both.

Off-balance sheet arrangements

We had no off-balance sheet arrangements during the quarter ended June 30, 2007.

Item 3(a)T. Controls and Procedures.

Management’s annual report on internal control over financial reporting

As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our President and Secretary, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our President and Secretary concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods and is accumulated and communicated to management, including our President and Secretary, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic Securities and Exchange Commission reports. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our President and Secretary have concluded that our disclosure controls and procedures are effective to a reasonable assurance level of achieving such objectives.

However, during our review, our auditors noted a significant deficiency in our internal controls and believe that our methodology for identifying all necessary disclosures could lead to a material misstatement of net income (loss).  We have addressed that weakness and feel that proper application of controls that have been put in place will eliminate such deficiencies in the future.

It should be noted, however, that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. In addition, we have reviewed our internal controls over financial reporting, and incorporated minor changes necessary during the period covered by this quarterly report.  

Changes in internal control over financial reporting

We had no changes in internal control over financial reporting during the period covered by this Quarterly Report.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None; not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

15

During the last three months we issued the following unregistered securities:

Name                                                              Number of Shares       Issuance Date        Consideration

LKB Partners, LLC	4,000,000	4/11/07	Consulting services
Frank Marra	1,000,000	4/11/07	Managerial services

We issued all of these securities to persons who were either “accredited investors,” or “sophisticated investors” who, by reason of education, business acumen, experience or other factors, were fully capable of evaluating the risks and merits of an investment in our company; and each had prior access to all material information about us.  We believe that the offer and sale of these securities were exempt from the registration requirements of the Securities Act, pursuant to Sections 4(2) and 4(6) thereof, and Rule 506 of Regulation D of the Securities and Exchange Commission and from various similar state exemptions.

Use of Proceeds of Registered Securities

Proceeds from the sale of registered securities received during the quarter ended March 31, 2007, totaled $100,000, from warrant exercises. These funds were primarily used for professional services and administrative expenses.  There were no proceeds from the sale of registered securities during the quarter ended June 30, 2007.

Purchases of Equity Securities by Us and Affiliated Purchasers

None; not applicable.

Item 3. Defaults Upon Senior Securities.

None; not applicable.

Item 4. Submission of Matters to a Vote of Security Holders.

None; not applicable.

Item 5. Other Information.

(a) None; not applicable.

(b) Nominating Committee

During the quarterly period ended June 30, 2007, there were no changes in the procedures by which security holders may recommend nominees to the Company’s Board of Directors.

Item 6. Exhibits

(a) Exhibits and Index of Exhibits.

None.

31.1 302 Certification of Thomas C. Drees, PH.D

31.2 302 Certification of David E. Nelson

32 Section 906 Certification.

16

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant has caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.

SANGUINE CORPORATION

Date:	8/2/07	By:	/s/Thomas C. Drees
			Thomas C. Drees
			CEO, President and Chairman of the Board of Director
Date:	8/2/07	By:	/s/David E. Nelson
			David E. Nelson
			CFO and Director

17